Abstract

The vascular fibrinolytic system is crucial for spontaneous lysis of blood clots. Plasminogen activator inhibitor 1 (PAI-1), the principal inhibitor of the key fibrinolytic enzyme tissue-type plasminogen activator (tPA), is present in platelets at high concentrations. However, the majority of PAI-1 stored in platelets has been considered to be inactive. Our recent finding (Brogren H, et al. Blood 2004) that PAI-1 de novo synthesized in platelets remained active for over 24 h, suggested that PAI-1 stored in the α-granules might be active to a larger extent than previously reported. To re-evaluate this issue, we performed experiments where the fraction of active PAI-1 was estimated by analyzing the tPA-PAI-1 complex formation. In these experiments platelets were lysed with Triton X-100 in the presence of serial dilutions of tPA and subsequently the tPA-PAI-1 complex was evaluated by Western blot. Also, using a non-immunologic assay, tPA was labeled with 125I, and 125I-tPA and 125I-tPA-PAI-1 was quantified by scintigraphy. Interestingly, both methods demonstrated that the majority (>50%) of platelet PAI-1 is active. Further analyses suggested that pre-analytical procedures used in previous studies (sonication or freezing/thawing) may have substantially reduced the activity of platelet PAI-1, which has lead to an underestimation of the proportion of active PAI-1. Our in vitro results are more compatible with the role of PAI-1 in clot stabilization as demonstrated in physiological and pathophysiological studies.

Highlights

  • In vivo clot lysis results primarily from activation of the fibrinolytic system by tissue-type plasminogen activator released from the vascular endothelium

  • Total plasminogen activator inhibitor 1 (PAI-1) antigen was determined using commercial ELISA kits, and type plasminogen activator (tPA) and tPA-PAI-1 complex was studied by Western blot analysis as well as with autoradiography and scintigraphy of 125I-labelled tPA

  • The average PAI-1 activity was estimated to 65% in samples analysed by Western blot and 53% in samples analysed with 125I-labelled tPA

Read more

Summary

Introduction

In vivo clot lysis results primarily from activation of the fibrinolytic system by tissue-type plasminogen activator (tPA) released from the vascular endothelium. The thrombolytic activity of tPA is regulated by specific inhibitors, the most important of which is plasminogen activator inhibitor 1 (PAI-1). Blood clots contain large amounts of PAI-1 that may originate from agranules of activated platelets [1]. Immuno-histochemical studies have shown that platelet-rich arterial clots contain 2 to 3 fold more PAI-1 than venous clots [2,3], and there is a close correlation between the relative PAI-1 content of a clot and its resistance to thrombolysis [4]. Studies in transgenic mice have shown that PAI-1 influences the resistance to thrombolysis and the rate of progression of thrombus formation following vascular injury [8]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call